Changes_NNS
in_IN
triiodothyronine_NN
-LRB-_-LRB-
T3_NN
-RRB-_-RRB-
mononuclear_JJ
leukocyte_JJ
receptor_NN
kinetics_NNS
after_IN
T3_NN
administration_NN
and_CC
multiple_JJ
cold-air_JJ
exposures_NNS
._.

Repeated_VBN
cold-air_JJ
exposures_NNS
increase_VBP
human_JJ
triiodothyronine_NN
-LRB-_-LRB-
T3_NN
-RRB-_-RRB-
plasma_NN
clearance_NN
rates_NNS
._.

To_TO
study_VB
the_DT
response_NN
of_IN
the_DT
nuclear_JJ
T3_NN
receptor_NN
-LRB-_-LRB-
NT3R_NN
-RRB-_-RRB-
in_IN
this_DT
condition_NN
,_,
binding_NN
characteristics_NNS
were_VBD
analyzed_VBN
in_IN
human_JJ
mononuclear_JJ
leukocytes_NNS
-LRB-_-LRB-
MNL_NN
-RRB-_-RRB-
._.

In_IN
addition_NN
,_,
we_PRP
supplemented_VBD
one_CD
group_NN
of_IN
individuals_NNS
with_IN
a_DT
daily_RB
oral_JJ
replacement_NN
dose_NN
of_IN
T3_NN
to_TO
isolate_VB
the_DT
influence_NN
of_IN
serum_NN
thyroxine_NN
-LRB-_-LRB-
T4_NN
-RRB-_-RRB-
and_CC
thyrotropin_NN
-LRB-_-LRB-
TSH_NN
-RRB-_-RRB-
levels_NNS
on_IN
receptor_NN
kinetics_NNS
._.

The_DT
subjects_NNS
were_VBD
exposed_VBN
to_TO
cold_JJ
air_NN
-LRB-_-LRB-
4_CD
degrees_NNS
C_NN
-RRB-_-RRB-
twice\/d_RB
,_,
30_CD
min\/exposure_NN
,_,
for_IN
a_DT
total_NN
of_IN
80_CD
exposures_NNS
._.

The_DT
T3_NN
-_:
subjects_NNS
received_VBN
placebo_NN
-LCB-_-LRB-
n_NN
=_JJ
8_CD
-RCB-_-RRB-
and_CC
the_DT
T3_NN
+_CC
subjects_NNS
received_VBD
T3_NN
-LRB-_-LRB-
30_CD
micrograms\/d_NN
-RRB-_-RRB-
-LCB-_-LRB-
n_NN
=_JJ
8_CD
-RCB-_-RRB-
in_IN
a_DT
double-blind_JJ
fashion_NN
._.

Mononuclear_JJ
leukocytes_NNS
were_VBD
isolated_VBN
from_IN
peripheral_JJ
blood_NN
before_IN
the_DT
cold_JJ
exposure_NN
and_CC
drug_NN
regimen_NN
began_NN
,_,
and_CC
then_RB
after_IN
every_DT
20_CD
exposures_NNS
._.

The_DT
dissociation_NN
constant_NN
-LRB-_-LRB-
Kd_NN
-RRB-_-RRB-
and_CC
maximum_JJ
binding_NN
capacity_NN
-LRB-_-LRB-
MBC_NN
-RRB-_-RRB-
of_IN
the_DT
NT3R_NN
values_NNS
were_VBD
log_NN
transformed_VBN
to_TO
minimize_VB
between-subject_JJ
variability_NN
._.

In_IN
the_DT
T3_NN
+_CC
group_NN
,_,
serum_NN
total_VBP
thyroxine_NN
-LRB-_-LRB-
TT4_NN
-RRB-_-RRB-
,_,
free_JJ
T4_NN
-LRB-_-LRB-
FT4_NN
-RRB-_-RRB-
,_,
and_CC
TSH_NN
were_VBD
approx_RB
50_CD
%_NN
lower_JJR
than_IN
both_CC
basal_JJ
and_CC
T3-values_NNS
._.

The_DT
log10Kd_NN
increased_VBD
0.304_CD
+_CC
\/_CD
-_:
0.139_NN
-LRB-_-LRB-
p_NN
&lt;_JJR
0.04_CD
-RRB-_-RRB-
and_CC
the_DT
log10MBC_NN
increased_VBD
0.49_CD
+_CC
\/_CD
-_:
0.10_NN
-LRB-_-LRB-
p_NN
&lt;_JJR
0.001_CD
-RRB-_-RRB-
in_IN
the_DT
T3_NN
+_CC
subjects_NNS
compared_VBN
to_TO
baseline_NN
._.

This_DT
change_NN
in_IN
MBC_NN
represents_VBZ
a_DT
311_CD
%_NN
increase_NN
in_IN
the_DT
MBC_NN
over_IN
baseline_NN
and_CC
a_DT
fivefold_JJ
increase_NN
over_IN
placebo-treated_JJ
subjects_NNS
._.

The_DT
T3_NN
-_:
group_NN
showed_VBD
no_DT
change_NN
in_IN
MBC_NN
over_IN
the_DT
study_NN
._.

These_DT
results_NNS
describe_VBP
for_IN
the_DT
first_JJ
time_NN
the_DT
rapid_JJ
modulation_NN
of_IN
the_DT
NT3R_NN
in_IN
response_NN
to_TO
the_DT
combined_JJ
influence_NN
of_IN
cold_JJ
exposure_NN
and_CC
reduced_VBN
circulating_VBG
T4_NN
and_CC
TSH_NN
._.

